Article Text

PDF
AB0630 Clinical spectrum time course comparison between PL-7, PL-12 and EJ positive antisynthetase syndrome
  1. E Trallero Araguas1,
  2. A O'Callaghan Selva1,
  3. CA Scire2,
  4. V Codullo3,
  5. S Castaneda4,
  6. N Ortego Centeno5,
  7. JA Pereira da Silva6,
  8. C Fiehn7,
  9. A Schwarting8,
  10. A Manfredi9,
  11. G Emmi10,
  12. S Barsotti11,
  13. O Molberg12,
  14. A Doria13,
  15. S Parisi14,
  16. S Scarpato15,
  17. N Pipitone16,
  18. M Piga17,
  19. I Cavazzana18,
  20. FJ Lopez-Longo19,
  21. J Bachiller-Corral20,
  22. M Benucci21,
  23. J Rojas-Serrano22,
  24. K Triantafyllias23,
  25. N Perez-Gomez24,
  26. G Cagnotto25,
  27. F Maurier26,
  28. L Quartuccio27,
  29. E Bartoloni Bocci28,
  30. P Tomietto29,
  31. R Caporali3,
  32. F Iannone30,
  33. MA Gonzalez-Gay31,
  34. L Cavagna3,
  35. on behalf of AENEAS collaborative group
  1. 1Internal Medicine, Vall d'Hebron General Hospital, Barcelona, Spain
  2. 2Reumatology, UOC Reumatologia, Azienda Ospedaliero Universitaria S. Anna, Ferrara
  3. 3Rheumatology, University and Irccs Foundation Policlinico S. Matteo, Pavia, Italy
  4. 4Rheumatology, Hospital Universitario de la Princesa, IIS-IP, Madrid
  5. 5Systemic Autoimmune Diseases Unit, Hospital Clínico San Cecilio, Granada, Spain
  6. 6Rheumatology, Centro Hospitalar e Universitário, Coimbra, Portugal
  7. 7Rheumatology, ACURA Centre, Baden Baden
  8. 8Rheumatology, University Hospital Johannes-Gutenberg, Mainz, Germany
  9. 9Rheumatology, Azienda Ospedaliero-Universitaria Policlinico, Modena
  10. 10Experimental and Clinical Medicine, University, Florence
  11. 11Rheumatology, AOU Pisana, Pisa, Italy
  12. 12Rheumatology, University Hospital, Oslo, Norway
  13. 13Rheumatology, University, Padua
  14. 14Rheumatology, Città della salute e della scienza, Torino
  15. 15Rheumatology, ASL Salerno, Scafati
  16. 16Rheumatology, S.Maria Hospital –IRCCS, Reggio Emilia
  17. 17Rheumatology, University, Cagliari
  18. 18Rheumatology, University and AO Spedali Civili, Brescia
  19. 19Rheumatology, Hospital General Universitario Gregorio Marañόn, Madrid, Italy
  20. 20Rheumatology, University Hospital Ramόn y Cajal, Madrid, Spain
  21. 21Rheumatology, Azienda Sanitaria di Firenze, S. Giovanni di Dio Hospital, Firenze, Italy
  22. 22Rheumatology, Instituto Nacional de Enfermedades Respiratorias, Ismael Cosío Villegas, Mexico city, Mexico
  23. 23Rheumatology, ACURA Centre, Bad Kreuznach, Germany
  24. 24Rheumatology, Hospital Clinico Universitario, Santiago de Compostela, Spain
  25. 25Rheumatology, Skane University Hospital, Lund, Sweden
  26. 26Medicine, HPMetz, Metz, France
  27. 27Rheumatology, Santa Maria della Misericordia Hospital, Udine
  28. 28Rheumatology, University, Perugia
  29. 29Rheumatology, Cattnara Hospital, Trieste
  30. 30Rheumatology, University, Bari, Italy
  31. 31Rheumatology, Hospital Universitario Marqués de Valdecilla, IDIVAL, University of Cantabria, Santander, Spain

Abstract

Background Arthritis, myositis and Interstital lung disease (ILD) represent the classic clinical triad of antisynthetase syndrome (ASSD). In anti Jo-1 positive patients, these findings may appear also during the follow-up. Even if a similar cumulative trend has been showed also in non anti Jo-1 positive ASSD, a head to head comparison of clinical spectrum time course in these patients is still lacking

Objectives To assess the clinical spectrum time course in non anti Jo-1 positive ASSD, according to different underlying non anti Jo-1 specificities

Methods Clinical, laboratory and instrumental data collection of anti PL-7, PL-12, and EJ positive patients from an international database of ASSD

Results We identified 63 (42%) anti PL-7, 66 (44%) anti PL-12 and 20 (14%) anti EJ positive patients, reporting their characteristics in table 1 (disease onset) and 2 (last follow-up). At disease onset, no substantial differences were observed. At the end of follow-up, we observed some differences between anti PL-12 and both anti PL-7 and anti-EJ positive patients. In particular, anti PL-12 positive patients presented less frequently ex-novo triad findings and had a reduced prevalence of myositis. From the clinical point of view, the main pattern of disease presentation was an isolated ILD in all groups at the onset and only in anti-PL12 positive ASSD at last follow-up.

Conclusions Our study seems to indicate that clinical spectrum time course of anti PL-12 positive ASSD is different from that of anti PL7 and of anti EJ positive ASSD. The clinical pattern associated with these two latter antibodies was very similar. Furthermore, anti PL-12 positive patients seems to have a more stable disease, with a less common occurrence of ex-novo triad findings during the follow-up

References

  1. Cavagna L. Medicine 2015.

  2. Cavagna L. CRAI 2016.

  3. Cavagna L. ARD 2016 (Abstract).

  4. Trallero Araguas E. Scand J Rheumatol 2016.

References

Acknowledgements To all members of the AENEAS collaborative group.

Disclosure of Interest None declared

Statistics from Altmetric.com

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.